Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Fig. 3

The expression of FXYD2 mRNA in different IDH mutation and 1p/19q col-deletion status in CGGA. The expression of FXYD2 mRNA in 516 glioma patients with different IDH mutation status (A) and different 1p/19q deletion status (C) was compared by student’s t-test. The expression of FXYD2 mRNA in patients with different IDH mutation status (B) and 1p/19q deletion status (D) was compared by student’s t-test in different WHO grades of glioma patients. There were 134 cases of WHOII, 198 cases of WHOIII and 184 cases of WHOIV. The expression of FXYD2 mRNA (E) in 516 glioma patients with different WHO classification was compared by ANOVA. Data represent mean ± SD

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us